Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Change in Receivables: 2009-2024

Historic Change in Receivables for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $6.5 million.

  • Ligand Pharmaceuticals' Change in Receivables rose 440.27% to $16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.3 million, marking a year-over-year increase of 1340.32%. This contributed to the annual value of $6.5 million for FY2024, which is 148.33% up from last year.
  • According to the latest figures from FY2024, Ligand Pharmaceuticals' Change in Receivables is $6.5 million, which was up 148.33% from $2.6 million recorded in FY2023.
  • Ligand Pharmaceuticals' Change in Receivables' 5-year high stood at $28.6 million during FY2021, with a 5-year trough of -$55.3 million in FY2022.
  • Moreover, its 3-year median value for Change in Receivables was $2.6 million (2023), whereas its average is -$15.4 million.
  • In the last 5 years, Ligand Pharmaceuticals' Change in Receivables surged by 202.35% in 2020 and then slumped by 293.31% in 2022.
  • Over the past 5 years, Ligand Pharmaceuticals' Change in Receivables (Yearly) stood at $26.1 million in 2020, then grew by 9.80% to $28.6 million in 2021, then plummeted by 293.31% to -$55.3 million in 2022, then skyrocketed by 104.70% to $2.6 million in 2023, then soared by 148.33% to $6.5 million in 2024.